100 related articles for article (PubMed ID: 6542746)
1. [Value of preoperative chemotherapy in the treatment of invasive cancer of the bladder].
Denis L; Hendrickx G; Braeckman J; Debruyne R
Acta Urol Belg; 1984; 52(4):579-82. PubMed ID: 6542746
[No Abstract] [Full Text] [Related]
2. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
3. The role of systemic chemotherapy in advanced bladder cancer.
van Groeningen CJ; Stoter G
Prog Clin Biol Res; 1984; 153():381-93. PubMed ID: 6382283
[No Abstract] [Full Text] [Related]
4. [Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].
Matveev BP; Figurin KM
Urol Nefrol (Mosk); 1998; (6):42-5. PubMed ID: 10051828
[TBL] [Abstract][Full Text] [Related]
5. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
[TBL] [Abstract][Full Text] [Related]
7. Preemptive (neoadjuvant) chemotherapy for invasive bladder cancer: a decade of experience.
Raghavan D; Pearson B; Tynan A; Watt WH; Wines RD; Rochford M; Langdon P; Duval P
Semin Urol; 1990 Nov; 8(4):285-90. PubMed ID: 2149466
[No Abstract] [Full Text] [Related]
8. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group.
Bono AV; Benvenuti C; Reali L; Pozzi E; Gibba A; Cosciani-Cunico S; Comuzzi U; Anselmo G
Prog Clin Biol Res; 1989; 303():533-40. PubMed ID: 2675010
[No Abstract] [Full Text] [Related]
9. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
10. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for outcome in invasive bladder cancer treated with alternating chemoradiotherapy.
Sanguineti G; Orsatti M; Sormani MP; Canobbio L; Curotto A; Tognoni P; Giudici S; Franzone P; Boccardo F; Vitale V
Cancer J Sci Am; 1997; 3(4):213-23. PubMed ID: 9263627
[TBL] [Abstract][Full Text] [Related]
13. [Systemic chemotherapy in bladder cancer].
Sengeløv L; Kamby C; von der Maase H
Ugeskr Laeger; 1993 May; 155(18):1363-8. PubMed ID: 8497967
[TBL] [Abstract][Full Text] [Related]
14. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
15. [Intra-arterial chemotherapy for invasive bladder cancer (T2-3N0M0)].
Maruyama T; Kondoh N; Nojima M; Yamamoto S; Mori Y; Shima H; Kamikonnya N; Hirota S; Nakao N
Hinyokika Kiyo; 2006 Jun; 52(6):445-9. PubMed ID: 16848358
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
Galante E; Ferroni C; Bianchi S; Megale C; Molinaro S; Maymone S
J Exp Ther Oncol; 1996 Jul; 1(4):237-41. PubMed ID: 9414410
[TBL] [Abstract][Full Text] [Related]
17. Treatment of high-stage bladder cancer: case for adjunctive chemotherapy.
Walther PJ
Semin Urol; 1993 May; 11(2):69-73. PubMed ID: 8362122
[No Abstract] [Full Text] [Related]
18. Perioperative chemotherapy for the management of primary local regional urothelial tumors.
Logothetis CJ
Prog Clin Biol Res; 1985; 201():359-66. PubMed ID: 3841594
[No Abstract] [Full Text] [Related]
19. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
[TBL] [Abstract][Full Text] [Related]
20. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study.
Vikram B; Chadha M; Malamud SC; Hecht H; Grabstald H
Cancer; 1998 Mar; 82(5):918-22. PubMed ID: 9486582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
